

Medication: Clopidogrel (Plavix)	PDN: 6982.02	Last Updated: March 8, 2013	PMD: Andrew Travers*	PDC: Steven Carrigan*	Page 1 of 2
---	---------------------	---------------------------------------	--------------------------------	---------------------------------	-------------

CLOPIDOGREL (Plavix)

1.0 Classification

- Platelet aggregation inhibitor

2.0 Mechanism of Action

- Irreversible blockade of adenosine diphosphate (ADP) receptor on platelet cell membranes, inhibiting platelet aggregation

3.0 Indications

- Acute coronary syndrome (STEMI)

4.0 Contraindications

- Hypersensitivity
- Active pathological bleeding

5.0 Precautions

- Administer with caution in patients on another platelet inhibitor

6.0 Route

- May be given PO

7.0 Dosage

- As part of pre-hospital fibrinolysis: 75mg for patients 75 years old and above; 300mg for patients less than 75 years old
- For direct-to-PCI patients: 300mg

8.0 Supplied

- 75mg and 300mg tablets

9.0 May Be Given By

- PCP/ICP/ACP/CCP

10.0 Adverse effects

- Bronchospasm
- Increased risk of bleeding
- Fever
- Neutropenia
- Thrombocytic Thrombocytopenic Purpura (TTP)

11.0 Special notes

- There is an increased risk of bleeding when clopidogrel is administered in conjunction with NSAIDs
- Pregnancy category C [if the patient will benefit from a Category C drug, it is generally used]

12.0 References

- Chest Pain Clinical Practice Guideline
- EHS STEMI Reperfusion Worksheet
- Compendium of Pharmaceuticals and Specialties (CPS)

*Electronically Signed

Copyright © Emergency Health Services